ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1598

Shrinking Lung Syndrome in Systemic Lupus Erythematosus Patients: A Diagnosis We Should Suspect More Often

Didem Saygin1, Chris Lau2, Marco Lopez-Velazquez3 and Kristin B. Highland4, 1Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, 2Pulmonary and Critical Care, Cleveland Clinic, Cleveland, OH, 3Internal Medicine, Cleveland Clinic, Cleveland, OH, 4Rheumatology.org, Cleveland Clinic, Cleveland, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Lupus and Pulmonary Involvement

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Shrinking lung syndrome (SLS) is a rare pulmonary manifestation of systemic lupus erythematosus (SLE) characterized by dyspnea, pleuritic chest pain, restriction on pulmonary function test (PFT), and signs of diaphragm dysfunction without evidence of significant pleuroparenchymal disease. We believe that lack of diagnostic criteria leads to misdiagnosis of SLS. Diagnosis of SLS requires careful evaluation of respiratory mechanics which includes spirometry, lung volumes, diffusion capacity, change in FEV1 (forced expiratory volume in one second) from sitting to supine, and consideration for specific diaphragm testing such as Sniff test, ultrasonography or electromyography (EMG). Careful consideration for mimickers of SLS such as obesity, pleural and central nervous system diseases should be considered since each has different management strategies. We report clinical, imaging and PFT characteristics of SLS in order to better understand the physiology seen in SLS and to increase awareness on this unsuspected entity.

Methods: We performed an electronic search of patients seen at the Cleveland Clinic between January 2005 – February 2017 with ICD-10 codes for SLE, restrictive lung disease, diaphragm dysfunction, or pleurisy. Clinical data were retrieved from the electronic medical records.

Results: Our search revealed 462 patients with SLE who had PFT results and a diagnostic code for restrictive lung disease, diaphragm dysfunction, or pleurisy. 38 of them were initially suspected to have SLS based on the opinion of their treating physician. Yet, only 27 patients had lung volumes (71%), and 20 had sitting/supine spirometry (53%). 35  had a chest X ray and/or computed tomography (92%). Sniff testing was performed in 7 cases, and showed abnormality in 70% of cases. EMG was done in  11 cases, and showed paresis/paralysis in 50% of cases. None had ultrasound of the diaphragm.

Ultimately, 8 out of 38 patients had a SLS diagnosis (Table). 30 patients had an alternative diagnosis including obesity (n=9), pleurisy (n=7), interstitial lung disease (n=4), severe pleural disease (n=4), asthma (n=2), emphysema (n=1), pneumonia (n=1) and rib fracture (n=1). 18 patients had a BMI ˃30 (47%), 5 had BMI ˃40 (13%). When present, lung volumes were useful to differentiate a restrictive pattern between diaphragm dysfunction and obesity related restriction. Diaphragmatic eventration and bibasilar infiltrates were the most common radiographic findings in SLS patients.

Conclusion: Our study showed that the majority of patients suspected with SLS had an alternative diagnosis. Almost one third of patients with suspected SLS did not have lung volumes or diaphragmatic function analysis done and almost half-of these patients did not have sitting/supine spirometry performed.  SLS is a diagnosis of exclusion and a comprehensive evaluation to exclude other reasons for a restrictive ventilatory defect is essential. 

 

 

 

 

 

 

Patients

FEV1%

FVC%

TLC%

RV%

FRC%

ERV

DLCO%

Sit/Sup reduction

1

43%

39%

72%

109%

86%

0.31

 

-42%

2

61%

54%

59%

87%

58%

0.19

50%

-24%

3

72%

69%

75%

81%

76%

0.73

69%

-10%

4

37%

36%

55%

73%

47%

0.06

38%

 

5

26%

23%

 

 

 

 

63%

-27%

6

31%

31%

48%

98%

57%

0.35

43%

-25%

7

29%

26%

55%

127%

66%

0.17

 

 

8

48%

51%

 

 

 

0.31

30%

-36%

Mean (±SD)

43±16%

41±15%

61±10%

96±19%

65±14%

30±23%

49±14%

-27±11

 


Disclosure: D. Saygin, None; C. Lau, None; M. Lopez-Velazquez, None; K. B. Highland, None.

To cite this abstract in AMA style:

Saygin D, Lau C, Lopez-Velazquez M, Highland KB. Shrinking Lung Syndrome in Systemic Lupus Erythematosus Patients: A Diagnosis We Should Suspect More Often [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/shrinking-lung-syndrome-in-systemic-lupus-erythematosus-patients-a-diagnosis-we-should-suspect-more-often/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/shrinking-lung-syndrome-in-systemic-lupus-erythematosus-patients-a-diagnosis-we-should-suspect-more-often/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology